AVBP Stock Overview
Operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ArriVent BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.11 |
| 52 Week High | US$36.37 |
| 52 Week Low | US$14.35 |
| Beta | 0 |
| 11 Month Change | -7.50% |
| 3 Month Change | 8.90% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 45.55% |
Recent News & Updates
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
Sep 24
ArriVent BioPharma: Bringing A Novel Cancer Drug From China
Sep 17Shareholder Returns
| AVBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.0% | 2.4% | 0.5% |
| 1Y | n/a | 15.6% | 30.7% |
Return vs Industry: Insufficient data to determine how AVBP performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AVBP performed against the US Market.
Price Volatility
| AVBP volatility | |
|---|---|
| AVBP Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVBP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVBP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 40 | Bing Yao | www.arrivent.com |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
ArriVent BioPharma, Inc. Fundamentals Summary
| AVBP fundamental statistics | |
|---|---|
| Market cap | US$980.92m |
| Earnings (TTM) | -US$81.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.1x
P/E RatioIs AVBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$81.05m |
| Earnings | -US$81.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVBP perform over the long term?
See historical performance and comparison